Page Image

The HemOnc Pulse

Blood Cancers Today and the Society of Hematologic Oncology bring you The HemOnc Pulse, a podcast hosted by Chadi Nabhan, MD, MBA, FACP, covering all topics in the world of hematologic oncology.

Advertisement
Advertisement
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 29, 2024
Drs. Dahiya and Spiegel return for the second half of a discussion on reports of secondary T-cell malignancies after CAR-T.
Listen Now
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 15, 2024
In episode four of the 2024 season, Dr. Coombs shares updates in CHIP from ASH 2023.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 29, 2024
Drs. Saurabh Dahiya and Jay Spiegel stop by The HemOnc Pulse to discuss the recent news on CAR-T therapies and the FDA.
Chadi Nabhan, MD, MBA, FACPMyelodysplastic Syndromes | February 14, 2024
This episode of The HemOnc Pulse features Dr. Shastri, a physician-scientist, who discusses latest news in MDS.
Chadi Nabhan, MD, MBA, FACPHodgkin Lymphoma | January 4, 2024
Susan Parsons, MD, MRP; Andrew Evans, DO, MBA, MSc; and Matthew Maurer, DMSc; discuss the HoLISTIC consortium.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | January 17, 2024
Dr. Usmani shares insights on the evolution in myeloma treatment since he first started practicing.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | January 17, 2024
Dr. Venugopal offers her thoughts on the investigational drug KER-050 in lower-risk myelodysplastic syndromes.
Jerald Radich, MDAcute Myeloid Leukemia | January 17, 2024
"MRD positivity is an indication to go to transplant in these patients,” Dr. Radich said.
Chadi Nabhan, MD, MBA, FACPAggressive B-Cell Lymphoma | December 14, 2023
In this episode of The HemOnc Pulse, Alan Skarbnik, MD, of Novant Health, discusses practice-changing research in DLBCL.
Chadi Nabhan, MD, MBA, FACPChronic Lymphocytic Leukemia | December 14, 2023
The debate on the future of Bruton's tyrosine kinase (BTK) inhibitors in CLL.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | December 19, 2023
Grzegorz Nowakowski, MD, recounts his experience serving on the FDA ODAC while reviewing the POLARIX data.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | November 16, 2023
We saw patients [who] were going to die, and it saved their life and then it's gone and it's shocking," she explained.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | November 2, 2023
Dr. Cortes chats about the “boom” in treatments for chronic myeloid leukemia (CML), and where he sees a need for balance.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | October 19, 2023
Elias Jabbour, MD, discusses the most burning questions in acute lymphoblastic leukemia (ALL).
Chadi Nabhan, MD, MBA, FACPMyeloma | October 5, 2023
Dr. Fonseca offers his thoughts on the future of multiple myeloma treatment and more.
Chadi Nabhan, MD, MBA, FACPAggressive B-Cell Lymphoma | September 14, 2023
Jonathan Friedberg, MD, MMSc, discusses the trial and its implications for the field.
Chadi Nabhan, MD, MBA, FACPMeeting News | September 13, 2023
Dr. Garcia-Manero discusses key data from the phase III COMMANDS trial.
Chadi Nabhan, MD, MBA, FACPChronic Lymphocytic Leukemia | August 24, 2023
Dr. Shadman rounds up the latest news on CLL from the summer conferences in this episode of The HemOnc Pulse.
Chadi Nabhan, MD, MBA, FACPAcute Myeloid Leukemia | August 10, 2023
The changes brought about by molecular characterization have a profound impact on real-world clinical care for AML.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | July 27, 2023
Nitin Jain, MD, discusses the data on venetoclax combinations in CLL and key frontline treatment considerations.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | August 7, 2023
Dr. Nowakowski discusses the L-MIND study and the "revolution in the treatment of DLBCL" in recent years.
Chadi Nabhan, MD, MBA, FACPAcute Myeloid Leukemia | July 26, 2023
Naveen Pemmaraju, MD, discusses the rare, ultrarare, and forgotten blood cancers on this episode of The HemOnc Pulse.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | August 1, 2023
Dr. Majhail explores strategies to improve access to CAR-T therapy.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | September 13, 2023
Drs. Vijenthira and Prica discuss their study and why its results differed from a similar study published in late 2022.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | August 1, 2023
Sagar Lonial, MD, FACP, discusses how he approaches frontline therapy for multiple myeloma and key MRD considerations.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | August 1, 2023
Alan Skarbnik, MD, of Novant Health, discusses treating patients with follicular lymphoma and the nuances involved.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | August 1, 2023
Amer Zeidan, MBBS, MHS, of Yale, discusses the impact of AML classification updates and treatment considerations.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | March 23, 2023
Drs. Kambhampati and Thiruvengadam discuss their study investigating the cost effectiveness of pola-R-CHP in DLBCL.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | August 1, 2023
Graham Collins, MD, discusses how to navigate the latest research in Hodgkin lymphoma.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | August 1, 2023
Dr. Bishop discusses the matter with host Chadi Nabhan, MD, MBA, FACP, and speaks about why CAR-T doesn't always work.

Updates From Other BCT Partners

Blood Cancer TalksBlood Cancer Talks | February 27, 2024
Dr. Dispenzieri, of the Mayo Clinic, joins the "Blood Cancer Talks" hosts to discuss how to treat and manage AL amyloidosis.
Blood Cancer TalksAcute Myeloid Leukemia | February 13, 2024
Dr. Patel and the hosts discuss the TRANSFORM-1 study, MANIFEST-2, AUGMENT-101, and more.
Blood Cancer TalksBlood Cancer Talks | January 31, 2024
Dr. Eyre and the hosts discuss lymphoma abstracts from ASH 2023, including the FLAIR trial and the SYMPATICO trial.
Blood Cancer TalksBlood Cancer Talks | January 24, 2024
Shernan Holtan, MD, and the hosts discuss recent data on graft versus host disease prophylaxis.
Blood Cancer TalksBlood Cancer Talks | January 10, 2024
Dr. Derman and the hosts discuss myeloma abstracts from ASH 2023, including the PERSEUS trial and the KarMMa-3 trial.
Blood Cancer TalksBlood Cancer Talks | December 5, 2023
Dr. Dickinson joins "Blood Cancer Talks" hosts to discuss phase I and II trials on DLBCL, follicular lymphoma, and more.
Advertisement
Advertisement